Angiographic morphology of restenosis after percutaneous transluminal coronary angioplasty

Restenosis after successful percutaneous transluminal coronary angioplasty (PTCA) occurs frequently. To better define the restenosis process, a quantitative analysis was performed of coronary angiographic morphologic characteristics at restenosis, before and immediately after PTCA. In 22 patients cine frames showing stenosis at its most severe narrowing were traced and quantitatively analyzed. Immediately after PTCA, stenosis diameter (0.7 +/- 0.3 to 1.9 +/- 0.6 mm, mean +/- standard deviation, p less than 0.05) was increased; percent stenosis (77 +/- 11 to 34 +/- 16%, p less than 0.05), neck index (1.2 +/- 1.4 to 0.5 +/- 0.6, p less than 0.05) and irregularity (9 of 22 patients) were decreased. At follow-up, quantitative coronary morphologic values in most cases were similar to those before PTCA. There were individual changes, which occurred in an unpredictable and highly variable fashion, so that average values were not changed. The eccentricity ratio was not significantly changed by angioplasty or at restenosis. Thus, although successful PTCA results in specific changes in angiographic coronary stenotic morphology, these are reversed by the restenosis process.     

Angiographic changes produced by percutaneous transluminal coronary angioplasty

Percutaneous transluminal coronary angioplasty (PTCA) is being used with increasing frequency in the treatment of patients with symptomatic coronary artery disease. Balloon inflation results in diverse angiographic findings, reflecting the great variety of anatomic and pathologic changes produced. The long-term effects of inflation on the underlying atherosclerotic lesion and the clinical outcome are unknown but may depend in part on the anatomic changes caused by the dilatation itself. To facilitate communication and evaluation of the results of PTCA, a classification of the angiographic findings and their potential mechanisms is presented. Recognition and analysis of these angiographic findings may be helpful in evaluating the long-term outcome of patients undergoing PTCA.     

Role of percutaneous transluminal coronary angioplasty in multivessel disease

Although percutaneous transluminal coronary angioplasty (PTCA) is being widely performed in patients with multivessel disease, the eventual role it will play will depend on several factors, including the immediate and long-term results, procedural risks and restenosis. An important consideration is that of completeness of revascularization. This is based on cardiac surgical experience, which has documented that if revascularization is complete, the clinical outcome will be improved. The importance of this concept has been borne out in practice. Although complete revascularization is ideal, it cannot be achieved in a substantial number of patients with multivessel disease because of the presence of old total occlusion that cannot be dilated, diffuse and distal disease or a planned dilation strategy. However, many patients with successful dilation but incomplete revascularization do well. In these patients, attempts are made to identify and then dilate a "culprit" lesion. Dilation of these most physiologically important stenoses often results in an excellent short-term outcome. Currently, 2 studies have been initiated to compare the role of PTCA with that of coronary artery bypass grafting for the treatment of patients with multivessel disease. For these studies, initial success and long-term outcome in terms of morbidity and mortality as well as cost considerations will be assessed. The results of these studies will help to put into perspective the complementary roles of PTCA and coronary artery bypass grafting.     

Angiographic changes thirty minutes following percutaneous transluminal coronary angioplasty

In order to ascertain whether coronary angiography performed immediately after the completion of successful percutaneous transluminal coronary angioplasty (PTCA) can be used as an index of the final outcome of the procedure, angiography was repeated thirty minutes post PTCA in twenty consecutive patients undergoing elective PTCA. Comparison of the pre PTCA, immediate post PTCA and thirty minutes post PTCA angiograms showed that the initial angiographic success of 77.8% improvement in lumen diameter from pre PTCA to immediate post PTCA was reduced by 16.2% to 61.6% thirty minutes later. We conclude that angiographic changes continue to occur in the immediate post PTCA period and that the immediate post PTCA angiogram may not represent the true outcome of the procedure.     

Angiographic findings when chest pain recurs after successful percutaneous transluminal coronary angioplasty

Angiographic and clinical characteristics of 102 consecutive patients who underwent coronary cineangiography for assessment of recurrent angina pectoris after successful percutaneous transluminal coronary angioplasty (PTCA) were reviewed. Based on angiographic findings, patients were classified as having restenosis (n = 63), development of new, significant coronary stenosis (n = 15), incomplete revascularization (n = 9) or no significant coronary artery disease (n = 15). Eighteen clinical and technical characteristics of the study group were analyzed as predictors of angiographic outcome. The groups did not differ in terms of age, gender, number of inflations performed, peak inflation pressure or in the pre- or post-PTCA stenosis or gradient. The time from PTCA to onset of recurrent angina was the most powerful predictor of angiographic outcome. Patients in whom symptoms developed within 1 month of PTCA usually had incomplete revascularization or no coronary narrowing. Restenosis was the most common explanation for chest pain 1 to 6 months after PTCA. Angina recurring more than 6 months after PTCA was usually due to development of new, significant coronary artery narrowings.     

Exercise echocardiography follow-up in percutaneous transluminal coronary angioplasty

Exercise echocardiography has emerged as an excellent tool in the diagnosis of coronary artery disease and has proven to correlate very closely with the distribution and extent of coronary stenoses. In this report we describe our experience with the use of this noninvasive technique in evaluating patients at various stages before, shortly after, and later after percutaneous transluminal coronary angioplasty (PTCA). Coronary restenosis following PTCA occurs at rates between 25% and 40% and currently available screening tests including clinical history, routine exercise electrocardiography, and thallium scintigraphy have proven disappointing correlating with the presence or absence of restenosis. We have found that exercise echocardiography is useful not only in identifying patients who have coronary disease and in predicting the extent and distribution of this disease, but also in demonstrating even very early after angioplasty left ventricular functional improvement both at rest and with exercise. Once patients are discharged from the hospital and followed serially over 5 years, we have found that this tool is extremely valuable in predicting not only coronary restenosis at the site(s) of angioplasty but is also highly predictive of the development of new coronary stenoses. The capabilities of exercise echocardiography to predict restenosis and new disease far exceed the reliability of exercise electrocardiography or the presence or absence of symptoms as indicators of these problems. We have found exercise echocardiography to be an unexcelled screening test in the management of angioplasty patients.     

Primary percutaneous transluminal coronary angioplasty in the setting of multivessel disease

Primary percutaneous coronary intervention of the culprit lesion is the treatment of choice for acute myocardial infarction, while treatment of the severe non culprit lesion is not indicated in the guidelines (Class III indication). More aggressive strategies that include initial treatment of the severe non culprit lesion may reduce the incidence of delayed occlusions in specific clinical settings. The two cases we describe support our point of view.     

Restenosis after multilesion percutaneous transluminal coronary angioplasty

Experience and new technical advances have resulted in an increasing number of patients with multivessel coronary disease who can be considered for percutaneous transluminal coronary angioplasty (PTCA). In selected patients with multivessel coronary disease, PTCA is a safe and effective procedure for the immediate relief of anginal symptoms. However, many questions remain regarding the long-term therapeutic benefit of the procedure. Few data are available on the incidence and clinical significance of restenosis after multilesion PTCA. Clearly, there is the potential for a higher rate of restenosis in patients who undergo dilatation of more than 1 lesion. Determination of restenosis rates after multilesion PTCA is important in the definition of expanded indications for this procedure. Because of the variations in definitions of restenosis and in patient selection factors, reported recurrence rates after multilesion PTCA are not easily compared between patient series. After multilesion dilatation the risk of developing at least 1 recurrent lesion ranges from 26% to 53% and appears to be greater than that reported for single lesion PTCA. Multilesion restenosis occurs in 7% to 21% of patients who undergo multilesion PTCA and is frequently observed in patients with recurrent symptoms. "Silent" multilesion restenosis (i.e., multiple lesion restenosis without symptoms) is rare. A higher risk of restenosis at one of several dilatation sites in a patient with extensive coronary disease should not be a deterrent in recommending multilesion PTCA to selected patients with multivessel coronary disease because the procedure provides important symptomatic relief to most. Further, recurrent narrowings are usually amenable to a second dilatation attempt if clinically indicated.     

Risk stratification after percutaneous transluminal coronary angioplasty

Summary Approximately 20–30% of patients who undergo elective percutaneous transluminal coronary angioplasty (PTCA) require a second angioplasty within 12 months. A significant proportion of patients develop clinical cardiac events during the first year following the initial procedure. The present investigation was undertaken to establish a statistical model for predicting such events. The study group consisted of 100 patients who underwent elective PTCA at the University of Alberta Hospital. All patients were prescribed nifedipine (10 mg tid) and aspirin (325 mg daily) in addition to other medications determined by the attending cardiologist. The patients were reviewed 10 weeks after the procedure and again at the end of 1 year.The follow-up was completed on 96 patients. Within the first year, forty-five experienced cardiac events (1 death, 5 myocardial infarctions, 4 bypass surgeries, 22 repeat PTCAs). These events occurred in 29 patients. An additional 16 patients experienced significant anginal symptoms. A statistical model based upon the patients' perception of symptoms immediately after the procedure, history of hypertension, vessel subjected to PTCA, ejection fraction pre-PTCA, and occurrence of intimal dissection during PTCA was used to identify patients likely to develop cardiac events. Overall, the model classified 72% of the patients (with and without events). Such a statistical model could be used to identify patients who should be subjected to an enhanced degree of cardiologic surveillance in a rehabilitation program.     

Pathological findings after percutaneous transluminal coronary angioplasty

Ten serial pathological cross sections at 1 mm intervals of both the left anterior descending artery at the site of a percutaneous transluminal coronary angioplasty and of the circumflex artery in the untreated stenotic area were studied at necropsy in a patient who died immediately after the procedure. The extent of calcification and atheroma were similar in both branches. Intimal or medial splitting, desquamation, and plaque fracture were present in the left anterior descending artery. No typical pathological findings were seen in the circumflex artery. This study suggests that the original stenotic lumen may have been enlarged as a result of plaque splitting.     

Coronary histology after percutaneous transluminal coronary angioplasty

This article describes previously unreported histologic changes in the vessels of a patient who was admitted with an evolving myocardial infarction due to subtotal occlusion of the left anterior descending coronary artery. The patient died of cardiogenic shock 15 hours after undergoing a technically successful percutaneous transluminal coronary angioplasty procedure. Upon early postmortem study, histologic sections from the proximal, middle, and distal thirds of the left anterior descending coronary artery were polymorphic in appearance. Sections from the most proximal angioplasty site revealed intimal proliferation of polymorphonuclear leukocytes, as well as intimal fibrosis with plaque cleavage. Sections from the more distal angioplasty sites revealed plaque cleavage, intimal polymorphonuclear infiltration, and intimal, medial, and adventitial fracture with dissecting hemorrhage, although mural integrity had been maintained. Intense subintimal proliferation with inflammatory cells has previously been described only in an experimental animal model. Our case also appears to be the first in which adventitial disruption has been observed after percutaneous transluminal coronary angioplasty; this finding provides new evidence that an atherosclerotic coronary artery can tolerate vigorous dilatation without rupture.     

Ischemic complications after percutaneous transluminal coronary angioplasty

The ischemic complications ofpercutaneous transluminal coronary angioplasty (PTCA) include abrupt closure, which occurs in 2% to 10% of patients and is associated with increased morbidity and mortality. Periprocedural myocardial infarction due to side branch occlusion or embolization of platelet aggregates or thrombus occurs in 5% to 20% of patients. Patients with acute coronary syndromes, older age, and complex lesions are at greater risk of periprocedural complications. Technical advances, primarily stenting, are useful in the prevention and management of acute closure, but are also accompanied by thrombotic complications. It remains to be seen whether the new antithrombin agents reduce the rate of periprocedural complications if used in combination with aspirin and new antiplatelet therapies. These new antiplatelet agents (ticlopidine, clopidogrel, abciximab, eptifibatide, and tirofiban) reduce the rate of ischemic complications and have become standard adjunctive therapy for patients who undergo PTCA.     

Long-term follow-up after direct percutaneous transluminal coronary angioplasty for acute myocardial infarction

Objectives. The purpose of this study was to analyze long-term follow-up information over several years from consecutive, unselected patients treated with direct percutaneous transluminal coronary angioplasty (PTCA) for acute myocardial infarction (MI).Background. Direct PTCA is often used in patients with acute MI. Short-term results are favorable. However, there is less information available on long-term observations over several years in these patients.Methods. A total of 416 consecutive and unselected patients with acute MI underwent direct PTCA. Survival of the acute infarct phase was 94.2%; the remaining 392 patients—the study population—were discharged and followed for 3.3 ± 1.4 years. Mortality as well as cardiac events and reinterventions are reported. Clinical variables assessed at the time of discharge are submitted to statistical analysis to detect potential risk factors.Results. Total cumulative mortality in the first year was 10% for the entire group and 6% for patients not presenting in cardiogenic shock. Mortality after discharge was 4.6% in the first year and dropped to <4% per year thereafter. Reinterventions after discharge were required in 16% in the first year and in <4% per year in years 2 to 4. Poor left ventricular ejection fraction (<35%), three-vessel disease and advanced age (≥75 years) were long-term risk factors for total mortality after direct PTCA.Conclusions. The clinical benefit of direct PTCA for acute MI is maintained during follow-up with respect to mortality. However, reinterventions for restenosis or de novo stenosis are often required (10% to 20%). Although few in number (<10%), patients with severely impaired left ventricular function continue to have a poor prognosis.     

Angiographic de novo appearance of a myocardial bridge after successful percutaneous transluminal coronary angioplasty

Background: NT-proBNP has prognostic implications in heart failure. In acute coronary syndromes (ACS) setting, the prognostic significance of NT-proBNP is being sought. We studied short-term prognostic impact of admission NT-proBNP in patients admitted for ACS and in association with GRACE risk score (GRS). Methods and Results: We studied 1035 patients admitted with ACS. Patients were divided in quartiles according to NT-proBNP levels on admission: Q1 <180 pg/ml; Q2 180–691 pg/ml; Q3 696–2664 pg/ml; Q4 2698–35 000 pg/ml. Groups were compared in terms of short-term all-cause mortality. Patients with higher NT-proBNP had worst GRS on admission. They also received less aggressive treatment. In-hospital mortality was 0.8%, 3.0%, 5.8% and 12.8% (P<0.001) and 30-day mortality 1.6%, 4.6%, 6.5% and 16.7% (P<0.001) respectively. In multivariate logistic regression analysis, NT-proBNP is an independent predictor of in-hospital (OR 2.35; 95% CI: 1.12–4.93, P=0.022) and 30-day mortality (OR 2.20; 95% CI: 1.17–4.12, P=0.014). However, NT-proBNP does not add any incremental benefit to GRS for prediction of outcome by ROC curve analysis. Conclusions: NT-proBNP is an independent predictor of in-hospital and 30-day mortality after ACS, independently of left ventricular function, but does not increase the prognostic accuracy of GRS.